Giordano Botta: VA and Allelica Partner on Clinical Study of PRS and PGx in Cardiovascular Prevention
Giordano Botta, CEO and Co-Founder of Allelica, shared a post on LinkedIn:
“We are proud to partner with the U.S. Department of Veterans Affairs, the largest integrated healthcare system in the United States, on a randomized clinical trial evaluating the impact of polygenic risk score (PRS) and pharmacogenomics (PGx) in routine care.
This comes at a pivotal moment, as the new 2026 ACC/AHA guidelines now include PRS as a risk enhancing factor.
The study will compare standard care with a genomic guided approach.
Patients in the intervention arm will receive the Allelica multi-ancestry PRS for coronary artery disease together with PGx testing for statin response, including SLCO1B1.
The objective is to assess whether integrating genetic risk and drug response can improve statin prescription, adherence, and ultimately cardiovascular outcomes.
We look forward to supporting this clinical trial, designed to generate prospective evidence on the clinical utility of integrating PRS and PGx into cardiovascular prevention, with the potential to inform implementation at scale across large healthcare systems.”
Stay updated with Hemostasis Today.
-
Nov 18, 2026, 15:11Vansh Yaduvanshi: Why Compatible Blood Groups Do Not Always Mean Compatible Blood
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: The Ecological Transition in Thrombosis and Haemostasis